[1] MAK LY,WONG DK,CHEUNG KS,et al. Review article:Hepatitis B core-related antigen(HBcrAg):An emerging marker for chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther,2018,47(1):43-54.
|
[2] ROKUHARA A,TANAKA E,MATSUMOTO A,et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment[J]. J Viral Hepat,2003,10(4):324-330.
|
[3] NASSAL M. HBV cccDNA:Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut,2015,64(12):1972-1984.
|
[4] LUCIFORA J,PROTZER U. Attacking hepatitis B virus cccDNA—The holy grail to hepatitis B cure[J]. J Hepatol,2016,64(1 Suppl):s41-s48.
|
[5] CHEN EQ,FENG S,WANG ML,et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B[J].Sci Rep,2017,7(1):173.
|
[6] CHEN EQ,WANG ML,TAO YC,et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA[J]. J Viral Hepat,2019,26(5):586-595.
|
[7] WANG ML,LIAO J,WEI B,et al. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBe Ag seroconversion in chronic hepatitis B patients with pegylated interferon therapy[J]. Infect Dis(Lond),2018,50(7):522-530.
|
[8] NIU JQ. Serum hepatitis B core-related antigen can predict outcome as a satisfactory surrogate marker in chronic hepatitis B patients[R]. San Francisco:AASLD,2018.
|
[9] SONG G,YANG R,RAO H,et al. Serum HBV core-related antigen is a good predictor for spontaneous HBe Ag seroconversion in chronic hepatitis B patients[J]. J Med Virol,2017,89(3):463-468.
|
[10] SETO WK,WONG DK,FUNG J,et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B[J]. Clin Microbiol Infect,2014,20(11):1173-1180.
|
[11] MAASOUMY B,WIEGAND SB,JAROSZEWICZ J,et al. Hepatitis B core-related antigen(HBcrAg)levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D[J]. Clin Microbiol Infect,2015,21(6):606. e1-10.
|
[12] Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection[J]. Hepatol Res,2014,44(Suppl 1):1-58.
|
[13] WANG ML,CHEN EQ,TAO CM,et al. Pronounced decline of serum HBs Ag in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy[J]. Scand J Gastroenterol,2017,52(12):1420-1426.
|
[14] WANG ML,DENG R,CHEN EQ,et al. Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy[J]. Clin Res Hepatol Gastroenterol,2019,43(3):301-309.
|
[15] WANG ML,CHEN EQ,TAO CM,et al. Letter:Serum HBcrAg is a useful marker for disease monitoring,predicting treatment response and disease outcome of chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther,2018,47(12):1719-1720.
|
[16] TADA T,KUMADA T,TOYODA H,et al. HBcrAg predicts hepatocellular carcinoma development:An analysis using time-dependent receiver operating characteristics[J]. J Hepatol,2016,65(1):48-56.
|
[17] CHEUNG KS,SETO WK,WONG DK,et al. Relationship between HBsAg,HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy[J]. J Viral Hepat,2017,24(8):654-661.
|
[18] HOSAKA T,SUZUKI F,KOBAYASHI M,et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy[J]. Liver Int,2010,30(10):1461-1470.
|
[19] HOSAKA T,SUZUKI F,KOBAYASHI M,et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues[J]. Aliment Pharmacol Ther,2019,49(4):457-471.
|
[20] TO WP,MAK LY,WONG DK,et al. Hepatitis B core-related antigen levels after HBe Ag seroconversion is associated with the development of hepatocellular carcinoma[J]. J Viral Hepat,2019.[Epub ahead of print]
|